• +1-646-491-9876
    • +91-20-67278686

    Search

    Integrin Beta 3-Pipeline Review H2 2017

    Integrin Beta 3-Pipeline Review H2 2017

    • Report Code ID: RW0001881478
    • Category Life Sciences
    • No. of Pages 65
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)-Pipeline Review H2 2017

    Summary

    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)-Integrin beta-3 (β3) or CD61 is a protein that in humans is encoded by the ITGB3 gene. Integrin beta 3 is found along with the alpha IIb chain in platelets. It is a receptor for cytotactin fibronectin laminin matrix metalloproteinase-2 osteopontin osteomodulin prothrombin thrombospondin vitronectin and von Willebrand factor. Activation of integrin alpha-IIb/beta-3 leads to platelet interaction through binding of soluble fibrinogen. This leads to rapid platelet aggregation which physically plugs ruptured endothelial surface.

    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) pipeline Target constitutes close to 20 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II IND/CTA Filed Preclinical and Discovery stages are 3 1 8 and 1 respectively. Similarly the universities portfolio in Preclinical stages comprises 7 molecules respectively. Report covers products from therapy areas Oncology Metabolic Disorders Ophthalmology Cardiovascular Dermatology Gastrointestinal and Infectious Disease which include indications Wet (Neovascular / Exudative) Macular Degeneration Glioblastoma Multiforme (GBM) Breast Cancer Diabetic Retinopathy Melanoma Arterial Thrombosis Cardiovascular Disease Diabetic Macular Edema Diabetic Nephropathy Ischemic Cerebral Stroke Lung Cancer Malabsorption Syndrome Metastatic Melanoma Multiple Myeloma (Kahler Disease) Myocardial Infarction Pancreatic Cancer Sepsis and Venous Leg Ulcers (Crural ulcer) .

    The latest report Integrin Beta 3-Pipeline Review H2 2017 outlays comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type. It also reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
    - The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)-Overview
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)-Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)-Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)-Companies Involved in Therapeutics Development
    Factor Therapeutics Ltd
    Merck & Co Inc
    SciFluor Life Sciences LLC
    SOM Biotech SL
    Vascular Pharmaceuticals Inc
    VDDI Pharmaceuticals
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)-Drug Profiles
    A-11-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AC-301-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C-16Y-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cilengitide-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Fusion Protein to Antagonize ITGA2B and ITGB3 for Arterial Thrombosis and Ischemic Cerebral Stroke-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MK-0429-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MSP-68-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OCU-200-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Proagio-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Protein to Agonize Integrin Alpha V Beta 3 and Beta 5 for Malabsorption Syndrome-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Antagonize VEGFR2 ITGB3 and ITGAV for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RSF-201-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RUC-4-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SF-0166-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SOM-0777-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tetraiodothyroacetic acid-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VF-001-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VPI-2690B-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    xemilofiban hydrochloride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)-Dormant Products
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)-Discontinued Products
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)-Product Development Milestones
    Featured News & Press Releases
    May 08 2017 Ocugen Expands Global Patent Portfolio for OCU200
    Apr 07 2017 Factor Therapeutics Phase II Clinical Trial Progress Update
    Dec 20 2016 Factor Therapeutics-First Patient In and Clinical Update
    Nov 07 2016 FDA Clinical Hold Lifted for IND 119526 (VF-001)
    Oct 17 2016 SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution
    Oct 10 2016 Submission of IND Amendments for Phase II Study of VF-001 in the US
    Aug 03 2016 Factor Therapeutics Announces Formation of Medical Advisory Board
    Aug 01 2016 SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases
    May 31 2016 New Class of Protein Could Treat Cancer and Other Diseases Georgia State Researchers Find
    May 25 2016 Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology
    Apr 02 2016 Iceni Pharmaceuticals announces appointment of cilengitide inventor Prof. Dr. Horst Kessler to its Scientific Advisory Board
    Mar 09 2016 SciFluor Life Sciences Awarded Second U.S. Patent for Integrin avß3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease
    Feb 11 2016 Ocugen Announces Patent Allowance For Ocu-200
    Dec 17 2015 Tissue Therapies Provides FDA Regulatory Progress Update
    Jun 30 2014 VDDI Provides Update On Xemilofiban
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Indication H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Number of Products under Investigation by Universities/Institutes H2 2017
    Products under Investigation by Universities/Institutes H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Pipeline by Factor Therapeutics Ltd H2 2017
    Pipeline by Merck & Co Inc H2 2017
    Pipeline by SciFluor Life Sciences LLC H2 2017
    Pipeline by SOM Biotech SL H2 2017
    Pipeline by Vascular Pharmaceuticals Inc H2 2017
    Pipeline by VDDI Pharmaceuticals H2 2017
    Dormant Products H2 2017
    Dormant Products H2 2017 (Contd..1) H2 2017
    Dormant Products H2 2017 (Contd..2) H2 2017
    Discontinued Products H2 2017

    List of Figures

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Top 10 Indications H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Factor Therapeutics Ltd
    Merck & Co Inc
    SciFluor Life Sciences LLC
    SOM Biotech SL
    Vascular Pharmaceuticals Inc
    VDDI Pharmaceuticals

    Request for Sample

    Report Url https://www.reportsweb.com//integrin-beta-3-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//integrin-beta-3-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//integrin-beta-3-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments